Generic remdesivir to cost up to $79 per dose

(By Alia Paavola for Becker’s Hospital Review)

Two generic drugmakers, Cipla and Hetero, were given the green light from Indian regulators to market their generic versions of remdesivir, a drug that has been authorized by the FDA for emergency use in treating patients with COVID-19.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org